glp-1 receptor agonists dizziness side effect Adverse effects of agonists: Clinical Implications, regulatory perspectives, and future directions Electrolytes for GLP-1 Dizziness: Why
Description
Andrej Jane has served as a consultant and is on Speakers Bureaus for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Medtronic, Abbott, Novo Nordisk, Novartis and Swixx
He now specializes in evidence-based weight management, including GLP-1/GIP therapies (semaglutide & tirzepatide)
The Type 2 Diabetes Mellitus segment accounted for the maximum share of over 55.5% by application in 2025 due to the high global disease burden resulting in rising demand for efficacious therapies for glycemic control
[DOI] [PubMed] [Google Scholar] 583.De Marinis Y.Z., Salehi A., Ward C.E., Zhang Q., Abdulkader F., Bengtsson M
